Search research articles
Contact Us
Filters
Showing results (531-540 of 560) with videos related to
Page
of 56
Sort By:
International Journal of Radiation Oncology, Biology, Physics
|
May 11, 2026
Impact of Tamoxifen Only after Lumpectomy for "Good Risk" Duct Carcinoma in Situ: Combined Analysis of the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trials
Jean L Wright, Jennifer Moughan, Wendy A Woodward, et al.
Hemasphere
|
May 22, 2024
Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
Fabio Efficace, Rena Buckstein, Gregory A Abel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 7, 2021
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131
Ingrid A Mayer, Fengmin Zhao, Carlos L Arteaga, et al.
Nature Immunology
|
December 30, 2025
Adenophages are an atypical macrophage population in exocrine glands sustained by ILC2-derived GM-CSF
Frederike Westermann, Selma Tuzlak, Victor Kreiner, et al.
Cancers
|
March 13, 2025
Epidemiology of Thyroid Cancer in Tuscany (Central Italy) 2013-2017: Not Just Overdiagnosis
Marco Capezzone, Liborio Torregrossa, Anello Marcello Poma, et al.
Thyroid : Official Journal of the American Thyroid Association
|
September 20, 2021
Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4)
Raffaella Forleo, Giorgio Grani, Marco Alfò, et al.
Cancer
|
January 18, 2024
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131
Karen L Smith, Fengmin Zhao, Ingrid A Mayer, et al.
Frontiers in Oncology
|
April 4, 2022
Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform
Fabio Efficace, Andrea Patriarca, Mario Luppi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2017
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline <i>BRCA1</i>- or <i>BRCA2</i>-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
George Somlo, Paul H Frankel, Banu K Arun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 13, 2014
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R Salgado, C Denkert, S Demaria, et al.
Page
of 56
Search research articles
Search
Showing results (531-540 of 560) with videos related to
Sort By:
Page
of 56
International Journal of Radiation Oncology, Biology, Physics
|
May 11, 2026
Impact of Tamoxifen Only after Lumpectomy for "Good Risk" Duct Carcinoma in Situ: Combined Analysis of the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trials
Jean L Wright, Jennifer Moughan, Wendy A Woodward, et al.
Hemasphere
|
May 22, 2024
Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
Fabio Efficace, Rena Buckstein, Gregory A Abel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 7, 2021
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131
Ingrid A Mayer, Fengmin Zhao, Carlos L Arteaga, et al.
Nature Immunology
|
December 30, 2025
Adenophages are an atypical macrophage population in exocrine glands sustained by ILC2-derived GM-CSF
Frederike Westermann, Selma Tuzlak, Victor Kreiner, et al.
Cancers
|
March 13, 2025
Epidemiology of Thyroid Cancer in Tuscany (Central Italy) 2013-2017: Not Just Overdiagnosis
Marco Capezzone, Liborio Torregrossa, Anello Marcello Poma, et al.
Thyroid : Official Journal of the American Thyroid Association
|
September 20, 2021
Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4)
Raffaella Forleo, Giorgio Grani, Marco Alfò, et al.
Cancer
|
January 18, 2024
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131
Karen L Smith, Fengmin Zhao, Ingrid A Mayer, et al.
Frontiers in Oncology
|
April 4, 2022
Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform
Fabio Efficace, Andrea Patriarca, Mario Luppi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2017
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline <i>BRCA1</i>- or <i>BRCA2</i>-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
George Somlo, Paul H Frankel, Banu K Arun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 13, 2014
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R Salgado, C Denkert, S Demaria, et al.
Page
of 56